NVO stock is down 30% over the past year because GLP-1 competition from Eli Lilly has compressed pricing power and tariffs have weighed on US demand — but 6 analysts still rate it a Buy with a $46.67 average price target after a Q1 2026 beat that drove a 7% post-print surge.
The stat that frames the entire NVO debate is simple: 30% one-year drawdown despite Wegovy and Ozempic generating record prescription volumes. Novo Nordisk (NYSE: NVO) trades at $44.87 — up 21.3% over the past 30 days as Q1 2026 numbers reset sentiment, but still 14.4% lower year-to-date and 30.1% below its level twelve months ago. The risk/reward favours bulls if you believe the GLP-1 franchise has been over-discounted; it favours bears if you think Eli Lilly’s tirzepatide momentum and US pricing pressure structurally compress margins. Below, we walk through what is dragging the NVO stock price lower, what the bulls see in 2026, and whether the recent 7% Q1 reaction is the start of a real bottoming pattern.
Key Takeaways
- Current price: NVO trades at $44.87, up 21.3% over 30 days but down 30.1% over 12 months and 14.4% YTD.
- Verdict: 6 analysts rate NVO a Buy with a $46.67 average price target.
- Bull case: Q1 2026 beat raised guidance; Wegovy demand running ahead of plan; LX9851 Phase 1 trial expands the pipeline.
- Bear case: Eli Lilly tirzepatide and Mounjaro continue to take share; US pricing pressure on GLP-1s is persistent.
- Catalyst: Semaglutide alcohol-use-disorder data and LX9851 Phase 1 readout could expand TAM.
NVO Key Stock Data
| Metric | Value |
|---|---|
| Current Price | $44.87 |
| 52-Week Range | ~$42 – $98 |
| Market Cap | ~$200 billion |
| P/E (TTM) | ~16x |
| Dividend Yield | ~2.0% |
| 1-Year Return | -30.1% |
| Analyst Consensus | Buy (6 analysts) |
| Average Price Target | $46.67 (range $36–$66) |
The bullish and bearish analyst opinions on Novo Nordisk converge on the recent operating numbers — the Q1 2026 beat was real and the Wegovy demand backdrop is genuinely strong — and diverge sharply on the durability of the franchise as Eli Lilly scales tirzepatide.
Table of Contents
- Key Takeaways
- NVO Key Stock Data
- What Is Novo Nordisk?
- Recent NVO Stock Performance
- Why Is NVO Down Today?
- NVO Valuation Analysis
- Bullish and Bearish Analyst Opinions on Novo Nordisk
- Named Analyst Price Targets for NVO
- How to Trade NVO via MEXC
- NVO Stock FAQs
What Is Novo Nordisk?
Novo Nordisk (NYSE: NVO) is a Danish pharmaceutical company that has built one of the most lucrative franchises in modern pharma around GLP-1 receptor agonists. Semaglutide powers two of the highest-selling drugs in the world: Ozempic for type 2 diabetes, and Wegovy for chronic weight management.
The thesis behind the NVO stock price rests on three legs. First, the global GLP-1 obesity market is still in early innings. Second, Novo Nordisk has multiple next-generation GLP-1 candidates in development. Third, the company is expanding into adjacent indications including alcohol-use disorder.
The challenge is competition. Eli Lilly’s tirzepatide has rapidly captured market share. Multiple other large-cap pharma companies — including Pfizer stock price — have advanced their own GLP-1 candidates, raising the prospect of structural pricing pressure. That competitive backdrop is what explains the gap between Novo Nordisk’s operating performance and the NVO stock price analysis sell-side desks have published.
Recent NVO Stock Performance
NVO stock has been a textbook case of multiple compression. The 1-year total shareholder return is -30.1%, which makes Novo Nordisk one of the worst performers among large-cap European pharma names over that window. Year-to-date, the stock is down 14.4%. Yet the recent 30-day return is +21.3% and the 7-day move is +9% — a sharp bounce after the Q1 2026 earnings print exceeded expectations.
Volume has expanded meaningfully on the recent rally days, which is consistent with short covering and incremental institutional accumulation. Implied volatility on NVO options has compressed from elevated post-2025 levels.
The 5-year total return remains positive at +26.3%. Long-term holders who entered before the 2023 obesity-trade peak are flat to modestly positive; investors who chased the rally near the high are still meaningfully underwater.
Why Is NVO Down Today?
- Eli Lilly tirzepatide momentum. Mounjaro and Zepbound have rapidly taken US prescription share.
- US pricing pressure. Inflation Reduction Act negotiations and payer pushback have compressed net pricing.
- Patent-cliff overhang. Semaglutide composition-of-matter protection faces a defined sunset window.
- Currency and geographic mix. A stronger US dollar through 2025 weighed on reported revenue.
- Sentiment unwind. The 2023–2024 GLP-1 obesity-trade rally drew significant momentum capital that has been actively rotating out.
The contrarian read is that all five drivers are now well known and meaningfully reflected in price. That gap is exactly what bulls cite when arguing the risk/reward favours accumulating on weakness.
Insider activity is also worth tracking. Several Novo Nordisk directors have purchased shares at current levels — typically a positive signal when it follows a sustained drawdown. Net institutional flows turned positive in early Q2 2026 for the first time since the GLP-1 trade peaked.
NVO Valuation Analysis
NVO trades at roughly 16x trailing earnings — a meaningful discount to its 5-year historical average near 28x and a steep discount to Eli Lilly stock price P/E levels above 50x.
| Valuation Method | NVO | Implication |
|---|---|---|
| P/E (TTM) | ~16x | Below 5-year average ~28x |
| Forward P/E (2026E) | ~14x | Cheap vs Lilly (~30x) |
| EV/EBITDA (2026E) | ~10x | Below pharma sector average |
| Dividend Yield | ~2.0% | Reasonable for large-cap pharma |
| Wall Street Average Target | $46.67 | ~5% upside |
| Most Bullish Target | $65.87 | ~47% upside |
The valuation table is meaningfully cheap on absolute and relative terms versus pharma peers. Bears argue the cheap multiple is a value trap; bulls argue it is a generational entry point.
Bullish and Bearish Analyst Opinions on Novo Nordisk
| Reasons for the Decline | Reasons the Drop Is Overdone |
|---|---|
| Eli Lilly tirzepatide taking share | Q1 2026 results beat and raised full-year guidance |
| US pricing pressure on GLP-1s | Wegovy international launches still ramping |
| Semaglutide patent-cliff overhang | LX9851 Phase 1 expands pipeline beyond semaglutide |
| Currency translation drag | Forward P/E ~14x vs Lilly ~30x |
| Momentum capital rotating out | Most-bullish target $65.87 implies ~47% upside |
Named Analyst Price Targets for NVO
- Wall Street Average — $46.67 (Buy): Across 6 covering analysts.
- Most Bullish — $65.87 (Buy): Bull-case analysts model Wegovy international launch upside.
- Most Bearish — $36.07 (Sell/Hold): Bear-case analysts assume tirzepatide takes meaningful US obesity share.
- MarketBeat consensus — $65.56: Higher-end target.
- Public.com consensus — $57.92: Mid-range target.
How to Trade NVO via MEXC
For investors outside the United States, MEXC offers tokenized exposure. The NVO USDT exchange pair allows users to trade Novo Nordisk 24/7 as a tokenized stock, settled in USDT, with no US broker required.
The tokenized format pairs naturally with broader healthcare exposure. Combined with MEXC’s Pfizer stock price and other healthcare stock tokens, traders can construct a multi-leg pharma basket.
NVO Stock FAQs
Why is NVO stock down?
Five overlapping pressures: Eli Lilly tirzepatide gaining US prescription share, US pricing pressure on GLP-1s, semaglutide patent-cliff concerns, currency translation drag, and momentum-capital rotation out of the GLP-1 trade.
Is NVO a buy after the drop?
Here’s the nuance: 6 analysts maintain a Buy consensus with a $46.67 average target — only 5% upside, but the upper-range target of $65.87 implies ~47% upside if the franchise stabilizes. The risk/reward favours bulls who believe Q1 2026’s beat marks the inflection.
Will NVO stock recover?
It depends on three factors. First, whether Novo Nordisk holds Wegovy market share against tirzepatide. Second, whether US net pricing stabilizes. Third, whether the next-generation pipeline produces clinical readouts that extend the franchise.
What are the bullish and bearish analyst opinions on Novo Nordisk?
Bulls anchor on the Q1 2026 beat, ongoing Wegovy international launches, the LX9851 Phase 1 trial, and the discounted forward P/E. Bears anchor on tirzepatide share gains, US pricing pressure, and the semaglutide patent-cliff timeline.
What is the NVO stock forecast for 2026?
The Wall Street average price target is $46.67, with a wide $36–$66 range. The bull-case scenario assumes Wegovy international upside drives mid-teen growth and the stock retests $60-plus.
How does Novo Nordisk compare to Eli Lilly?
Novo Nordisk has a more concentrated GLP-1 franchise but trades at a much lower forward P/E multiple. Eli Lilly has a broader pipeline including Alzheimer’s and oncology contributions plus the leading tirzepatide franchise, but trades at roughly twice Novo Nordisk’s multiple.
Disclaimer
This article is for informational purposes only and does not constitute financial advice or a recommendation to buy or sell securities.
MEXC is a global cryptocurrency exchange committed to “MEXCmize Your Opportunities.” Serving over 40 million users across 170+ countries, MEXC offers access to more than 3,000 digital assets across spot and derivatives markets.
